SAN FRANCISCO, Aug. 2, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that positive results from a proof-of-concept clinical trial using JX-594 to treat patients with metastatic melanoma were published in the peer-reviewed journal Molecular Therapy.
"This clinical trial in metastatic melanoma provides additional key information for our JX-594 program and complements the ongoing clinical development of JX-594, which is expected to enter a randomized Phase 2b trial in advanced liver cancer later this year," said David Kirn, M.D., president and chief executive officer of Jennerex. "Specifically, JX-594 replication was observed following multiple rounds of intratumoral JX-594 therapy, providing proof-of-concept data for the potential benefit of chronic administration regimens of the product."
The mechanistic proof-of-concept study enrolled 10 treatment-refractory Stage IV melanoma patients, eight of whom completed the study. All patients received up to nine weekly intratumoral injections of JX-594 at a low dose (less than 10 percent of the dose given in other JX-594 trials). Evidence of JX-594 activity was assessed in blood samples and tumor biopsies. Blood samples collected over the course of treatment demonstrated JX-594 replication after repeated dosing as well as the expression and functionality of JX-594 encoded transgenes. Tumor biopsies showed tumor cell necrosis (death) and immune cell recruitment into tumors. JX-594 was safe and well-tolerated, with flu-like symptoms as the most common side effect for patients.
JX-594: A Multi-Mechanistic Approach To Targeting Cancer
JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of act
|SOURCE Jennerex, Inc.|
Copyright©2010 PR Newswire.
All rights reserved